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MicroRNA-302 switch to identify 
and eliminate undifferentiated 
human pluripotent stem cells
Callum J. C. Parr1,*, Shota Katayama1,*, Kenji Miki1, Yi Kuang1, Yoshinori Yoshida1, 
Asuka Morizane2, Jun Takahashi2, Shinya Yamanaka1,3 & Hirohide Saito1
The efficiency of pluripotent stem cell differentiation is highly variable, often resulting in heterogeneous 
populations that contain undifferentiated cells. Here we developed a sensitive, target-specific, and 
general method for removing undesired cells before transplantation. MicroRNA-302a-5p (miR-302a) 
is highly and specifically expressed in human pluripotent stem cells and gradually decreases to basal 
levels during differentiation. We synthesized a new RNA tool, miR-switch, as a live-cell reporter mRNA 
for miR-302a activity that can specifically detect human induced pluripotent stem cells (hiPSCs) 
down to a spiked level of 0.05% of hiPSCs in a heterogeneous population and can prevent teratoma 
formation in an in vivo tumorigenicity assay. Automated and selective hiPSC-elimination was achieved 
by controlling puromycin resistance using the miR-302a switch. Our system uniquely provides sensitive 
detection of pluripotent stem cells and partially differentiated cells. In addition to its ability to eliminate 
undifferentiated cells, miR-302a switch also holds great potential in investigating the dynamics of 
differentiation and/or reprograming of live-cells based on intracellular information.
Induced pluripotent stem cell (iPSC) technology holds great promise for regenerative medicine while circum-
venting the ethical and practical issues surrounding the use of stem cells from embryonic sources. Furthermore 
iPSC technology allows for personalized medicine that give targeted therapy without immune complication. In 
addition, iPSC technology is proving to be a vital tool for disease modelling, creating more realistic cell-models 
from patients with all the complicated genetic and epigenetics pre-programmed. Since the initial discovery of the 
induced reprogramming mechanism for mouse and then human cells in 2006 and 2007 respectively, iPSCs have 
been differentiated into to numerous types of somatic cells1,2. Methods for cell reprogramming follow broadly 
two main strategies: (1) Direct cell-fate conversion in which genetic manipulation is required to overexpress tran-
scription factors and/or microRNAs. (2) The use of compounds, cytokines and/or recombinant signal peptides 
that stimulates reprogramming. The latter method is preferred for clinical application but often gives lower effi-
ciencies. These protocols have largely been adapted from the pre-existing methods using embryonic stem cells3–5. 
However, in the case of iPSCs, studies suggest the differentiation is highly dependent on the line, which may cause 
some practical issues for therapy6,7.
An important issue to be solved before iPSC-base therapies enter the clinic is the carryover of undifferenti-
ated iPSCs, partially differentiated cells, and wrongly differentiated cell types during transplantation. This problem 
arises, as no protocol is 100% efficient in generating the correct lineage let alone the target cell type. Furthermore, 
the differentiation efficiency can vary greatly depending on which iPSC clone is used because of the variable expres-
sion of key genes, including ones driven by human endogenous retrovirus type-H long-terminal repeats, which may 
be inhibitory to certain lineages8,9. In one study, several iPSC lines differentiated into midbrain neuronal lineage 
were found to be differentiation-defective, and the resulting cell population contained residual iPS cells that caused 
graft overgrowth when transplanted to mice. Even when no residual iPS cells were detected, the transplanted cells 
from certain lines lead to graft overgrowth due to partially differentiated cells8. Therefore, there is a real need to not 
only make sure transplanted cells are devoid of residual pluripotent cells but also partially differentiated cells that 
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may lead to graft overgrowth. Recent tumorigenesis experiments have found as few as 100 pluripotent stem cells 
transplanted to Severe Combined Immunodeficiency (SCID) mice can lead to teratoma growth10,11.
For certain cell types, there are no effective cell-surface or intracellular markers for their positive selection 
by cell sorting. Furthermore, in some cases, a mix-culture of cells, that excludes harmful cells to cause teratoma 
formation or graft overgrowth, is required. In the above cases, ideally we would use a general tool that can remove 
the undifferentiated or partially differentiated cells, while also being applicable to any differentiation protocol 
(Fig. 1a, top). Here we have established such a method, which can selectively identify undifferentiated and par-
tially differentiated cells with high-resolution. The method is simple and cost-effectively, and can also be easily 
scaled up to handle millions of cells. It is noteworthy that our method is the only one capable of interrogating the 
intracellular information of living cells. Comparatively, most existing technologies are restricted to information 
displayed on the cell surface.
Our technology, microRNA switches (miR-switches), were encoded on modified mRNA (modRNA)12,13 that 
post-transcriptionally regulates fluorescent reporters in response to the activity of the human miRNA-302/367 
cluster expressed in living cells (Fig. 1a, bottom). This cluster is important for maintaining the self-renewal 
of stem cells and particularly in the primed state of pluripotency14–17. The high dynamic range in expression 
between pluripotent and differentiated cells of miR-302a allows for very sensitive detection. In the present work, 
we could reproducibly detect spiked hiPSCs down to 0.05% of the total cell number using the miR-302a switch. 
Furthermore, due to the dynamic regulation of the fluorescence we could identify cells transitioning from the 
undifferentiated to differentiated stage at high-resolution, thus allowing us to discriminate sub-populations, such 
as partially differentiated cells, and isolate or eliminate them. In addition, by sorting hiPSC spiked midbrain 
dopaminergic (mDA)-like neuronal cell cultures with miR-302a switch, we could prevent teratoma formation in 
a standard in vivo tumorigenicity assay on mice. Lastly, we placed the miR-302a switch in the control of puromy-
cin selection to automatically and selectively remove contaminating hiPSCs, thus removing the necessity for cell 
sorting, which is time consuming and can damage the cells.
Results
Generation of live-cell reporters to detect pluripotency-specific miR-302/367 activity. We focused 
on the miR-302/367 cluster as previous reports have illustrated this cluster to be intrinsically involved in the regu-
lation of pluripotency15,17–19. We first confirmed the specific and high level of expression of both hsa-miR-302a-5p 
(herein referred to as miR-302a) and hsa-miR-367-3p (herein referred to as miR-367) in three feeder-free human 
iPSC lines (201B7, 1231A3, and 1383D7). We found the expression of miR-302/367 in the iPSC lines to be 102–6-
fold greater than spontaneously differentiated 201B7 cells (cells cultured without basic growth factor (bFGF) for 
2 weeks), 201B7-derived mDA cells, standard culture lines of NHDF and HeLa, and lastly primary hepatocytes 
and renal cells (Fig. 1b and Supplementary Fig. 1a).
We generated in vitro transcribed modRNA that encoded miR switches that can sensitively and dynamically 
respond to the activities of miR-302a and miR-367 in living cells. Translational repression of the reporter protein 
(human codon optimised azamin green, hmAG) occurs when the mature miRNA binds to an antisense sequence 
that is optimally placed within the 5′ -UTR (Fig. 1a, bottom) of the mRNA12,13. Normalizing this reporter expres-
sion to an internal fluorescent control (tag blue fluorescent protein, tagBFP) that is co-transfected produces nor-
malized translation efficiency (T.E, refer to methods). In the absence of the miRNA, the hmAG:tagBFP expression 
ratio is approximately 1:113. However with the presence of the miRNA, translation from the reporter is repressed, 
causing a downward shift in hmAG fluorescence on the dot-plot as illustrated in Fig. 1a, with cells within 
dotted-gate being the positive (pos) fraction responding to the miR-switch. 201B7 cells transfected with either 
miR-302a (green, Fig. 1c) or miR-367 (purple, Fig. 1c) switches are spatially resolved from cells transfected with 
miR switch containing no miRNA antisense sequence (Ctrl-miR switch, black dots), whereas most HeLa cells 
transfected with the three switches overlapped each other (Fig. 1c). From these results, we decided to focus on 
miR-302a switch for the following reasons: (1) From three independent experiments, the percentage of hiPS cells 
responsive to the miR-302a switch (positive = 97.05%, SEM ± 3.18) than those that responded to the miR-367 
switch (pos = 81.45%, SEM ± 19.97) (Fig. 1c); (2) When measuring the translational efficiency from the dot plots 
the miR-302a switched-transfected hiPS cells gave a higher fold-change than miR-367 switch-transfected cells 
(Fig. 1d); (3) And the miR-302a switch could completely separate 201B7 from NHDF and HeLa cells, whereas the 
miR-367 switch did not (Fig. 1e).
We next checked whether the repression on translation efficiency by the miR-302a switch was indeed specific 
to the miR-302a-5p activity. We co-transfected 201B7 cells with 15 pmol of either a control (green bar) or miR-
302a specific (grey bar) miRNA inhibitor (Supplementary Fig. 1b). Co-transfection of the 302a miRNA inhibitor 
allowed for recovery of the T.E. (Supplementary Fig. 1b,c). We next co-transfected varied amounts of the miRNA 
inhibitor in 201B7 and a miRNA mimic in HeLa cells to simulate the dynamic range of the miR-302a switch. In 
transfected cells, the increasing amount of 302a miRNA inhibitor caused a gradual recovery in the translational 
efficiency (hmAG/tagBFP). In contrast, the increasing amount of the 302a mimic caused a gradual repression in 
the translational efficiency in HeLa cells (Supplementary Fig. 1d). These results indicate miR-302a activity regu-
lates the miR-302a switch specifically.
miR-302a switch effectively separates hiPSCs and hiPSC-derived differentiated cells. In addi-
tion to checking standard culture lines and primary cells, we also tested our miR-302a switch on hiPSC-derived 
differentiated cells. We spontaneously differentiated hiPSCs by removing bFGF from the medium for 14 days. 
Again, proving that miR-302a switch is specific to pluripotent stem cells, there was a complete overlap of 
201B7-derived spontaneously differentiated cells transfected with either Ctrl-miR or miR-302a switch (Fig. 2a), 
suggesting that miR-302a switch distinguishes hiPSCs and differentiated cells. Furthermore, when using the 
same differentiation protocol on a differentiation-defective version of 201B7, 201B7-DD″ (see methods and 
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Figure 1. miR-302a and 367 switches specifically detect hiPSC cells. (a) miR-302a switch can remove 
undifferentiated or partially differentiated cells before transplantation. miRNA binding to the 5′ UTR of the 
hmAG reporter causes translation repression. The dotted outline on the dot-plot corresponds to the miR-
pos fraction. (b) hsa-miR-302a-5p and -367-3p are specifically expressed in 201B7 hiPSCs relative to NHDF 
and downregulated in spontaneously differentiated 201B7 cells and 201B7-derived mDA cells (n = 3 for all 
groups). (c) Representative dot plots of 201B7 and HeLa transfected with either 45 ng of Ctrl- (black dots), 
miR-302a (green) or miR-367 (purple) switches mRNA and 90 ng of tagBFP internal control. Right panel 
shows the percentage of 302-pos and 302-neg cells (n = 3 for all groups). (d) Percentage of translation efficiency 
(T.E., geometric mean of hmAG/geometric mean of tagBFP) of three hiPSC lines and NHDF cells transfected 
with Ctrl- (black), miR-302a (green) or miR-367 (purple) switches (n = 3 for all groups). (e) Representative 
histograms of the translation efficiency of the raw fluorescence signal (hmAG/tagBFP) for 201B7, HeLa and 
NHDF transfected with either miR-302a (top) or miR-367 (bottom). Error bars represent the SEM of three 
independent experiments.
www.nature.com/scientificreports/
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Figure 2. miR-302a switch distinguishes hiPSCs and hiPSC-derived differentiated cells. (a) LEFT PANELS 
Representative dot plots of 201B7 cells transfected with either 45 ng of Ctrl-miR (black) or miR-302a (green) 
switches and 90 ng of tagBFP at day 0 or day 14 in hiPSC medium (-bFGF) condition. Below Percentage of 302-
pos and 302-neg cells (n = 3 for all groups). RIGHT PANELS Representative dot plot of the 201B7-DD″ after 
14 days differentiation transfected with either Ctrl-miR (black) or miR-302a (green) switches. The far right plot 
shows the same cells stained with Alexa 647-conjugated IgG control (black shade) or Alexa-647-conjugated 
anti-TRA-1-60 antibody (blue shade). Below Percentage of 302-pos and 302-neg cells (n = 3 for all groups).  
(b) Representative dot plots of 201B7 cells differentiated with the mDA protocol and transfected with 45 ng of 
miR-302a switch (green) and 90 ng of tagBFP. Cells were analysed at days 5, 7, 9 and 14 of the differentiation.  
(c) Percentage of 302-pos cells versus time (day 0 to 14) for cells derived from 201B7 or 1231A3 hiPSC lines 
(n = 3 for all groups). (d) Percentage of TRA-1-60-pos cells versus time (day 0 to 14) for cells derived from 
201B7 or 1231A3 lines (n = 3 for all groups). (e) Representative histograms of Alexa 488-conjugated IgG 
staining (black shade) or CORIN staining (blue shade) for mDA cells derived from 201B7 or 1231A3 at day 12. 
Error bars represent the SEM of three independent experiments.
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Supplementary Fig. 2), after 14 days we could detect residual differentiation resistant cells (14.6 ± 3.4%) when 
transfecting miR-302a switch (Fig. 2a). This ratio was very similar to the percentage of cells that were positive for 
TRA-1-60 (a cell surface marker for hPSCs) antibody (14.2 ± 2.5%).
Monitoring differentiation dynamics and efficiency using miR-302a switch. We next tested our 
miR-302a switch on another hiPSC-derived differentiated cell type. We produced mDA neuronal cells using an 
established protocol (Supplementary Fig. 3a,b)5,8,20. After 14 days, like the results for spontaneously differentiated 
cells, the mDA neurons transfected with miR-302a switch overlapped with those transfected with Ctrl-miR switch 
(Fig. 2b, D14). These results further confirm that miR-302a switch can reproducibly distinguish hiPSCs and their 
differentiated cells. Moreover, the gradual recovery in translational efficiency in the representative dot plots from 
days 5, 7 and 9 (Fig. 2b), indicates that the level of active miR-302a in the cells gradually decreased during dif-
ferentiation. Using two hiPSC lines, we analysed the percentage of 302-positive (302-pos) cells at the same time 
points. Interestingly, we saw significant differences between 201B7 and 1231A3 lines. This difference was most 
noticeable at days 7 and 9, when the 302-pos cell population in 201B7 differentiated cells was 68.55 ± 7.97% and 
38.95 ± 0.15%, respectively, but in 1231A3 it was lower at 37.78 ± 5.23% and 8.81 ± 4.99% (Fig. 2c). In both lines, 
the percentage of TRA-1-60-pos cells decreased to near background level by day 5, suggesting that TRA-1-60 
antibody cannot distinguish these lines after 5 days of differentiation (Fig. 2d). To assess the differentiation effi-
ciency to the mDA identity, we stained the cells for CORIN expression, since staining for this cell-surface protein 
was recently found to enrich mDA cells20, and analysed the cells by flow-cytomery at day 12. The 1213A3 line 
consistently produced a higher number of CORIN-pos cells than the 201B7 line (see representative histograms in 
Fig. 2e). These data suggests miR-302a switch can detect partially differentiated cells (e.g., the cells after 9 days of 
differentiation in Fig. 2b,c). Thus, miR-302a switch can assay the differentiation dynamics and optimal condition 
and clone for directed differentiation.
Sensitive detection of spiked-hiPSCs using miR-302a switch. To facilitate the therapeutic applica-
tion of iPSC technology, it is important to detect and eliminate residual harmful cells with high sensitivity. Thus, 
as a next step, we moved from single- to co-cultured cell populations to check whether miR-302a switch could 
isolate hiPSCs from differentiated cells in a mixed culture. To this end, we took 201B7-derived mDA day 12 cells 
(2 × 105 cells) and spiked with a decreasing number of hiPSCs, from 1 × 104 (5% spike) to just 100 cells (0.05% 
spike) (Fig. 3). The entire volume of the cell-suspension was analysed by flow-cytometry. We successfully detected 
hiPSCs at all the spiked levels with miR-302a switch. The percentage of 302-pos cells closely matched that of TRA-
1-60-pos cells (Fig. 3b and Supplementary Fig. 4).
miR-302a switch sorting on partially differentiated mDA neuronal cultures. As a proof of prin-
ciple that our miR-302a switch can be used to make cultures safer for transplantation, we deliberately suspended 
the mDA differentiation of hiPSC cells at day 4 (cells after 4 days of differentiation contain undifferentiated and/
or partially differentiated cells in our mDA induction protocol). These cells were then transfected with miR-
302a switch and underwent FACS the following day to separate 302-pos and 302-negative (302-neg) cells (see 
scheme in Fig. 4a). We then re-cultured an equal number of 302-pos and 302-neg sorted cells to new plates and 
grew them for a further 7 days in hiPSC-culture medium to promote the growth of any residual harmful cells. 
We first confirmed the 302-pos and 302-neg sorted fractions from cells on day 5 for RNA analysis. We meas-
ured the expression of miR-302a and miR-367 and then expression of key pluripotent-, neuroectoderm- and 
mDA-associated mRNAs. As expected, the 302-neg sorted fraction contained a reduced level of both miR-302a 
and miR-367 relative to 302-pos sorted fraction (Fig. 4b). Furthermore, the 302-neg sorted fraction had a lower 
expression level of the pluripotency marker OCT4, higher expression levels of the neuroectoderm marker PAX6 
and of the midbrain marker EN1 (Fig. 4c). After 7 days of continuous culture in hiPSC culture medium, the cells 
were fixed and stained with an alkaline phosphatase (ALP) kit to detect hiPSC colony formation. This staining 
is often used to screen for colonies during iPSC reprogramming21. Over three independent sorting experiments, 
a significant number of ALP+ iPS-like colonies were observed in wells seeded with either non-sorted (5 ± 3 
colonies) or 302-pos sorted cells (22 ± 6) (Fig. 4d). In contrast, we saw no colonies in the wells re-cultured with 
302-neg sorted cells. For comparison, we also sorted day 5 mDA cells based on TRA-1-60 staining and as above 
re-cultured for 7 days an equal number of the TRA-1-60-pos and TRA-1-60-neg cells. As expected, wells seeded 
with TRA-1-60-pos cells had an even higher number of colonies (45 ± 5 colonies). Interestingly, TRA-1-60-neg 
cells also went on to form ALP+ colonies (21 ± 3 colonies), illustrating the high sensitivity of miR-302a switch, 
which can be used to remove harmful overgrowing cells.
miR-302a switch-sorted hiPSC-spiked co-cultures could prevent teratoma formation in SCID 
mice. To investigate whether miR-302a switch could prevent teratoma formation in iPSC-mixed cell popula-
tions, we spiked mDA day 20 cultures with hiPSCs and then transfected the cells with either Ctrl-miRNA switch 
or miR-302a switch. To show that we could effectively remove the spiked hiPSC cells, we transplanted the sorted 
miR-302-neg cells into the testes of SCID mice for allogeneic engraftment. If any residual hiPSCs remained after 
sorting, these cells would form teratomas. Teratoma formation containing all cells of the three germ layers is the 
main standard to prove an iPSC line is truly pluripotent22–24. We chose an initial seeding density in 12-well plates 
of 60,000 spiked hiPSC cells with 240,000 201B7-dervied mDA cells (20% hiPSC) per well to show the strategy 
can handle a relatively high number of spiked hiPSCs (Fig. 5a). The sorted cells were transplanted into the testes 
of the animals and left to engraft for 3 months. miR-302a switch sorted cells (302-neg) effectively removed spiked 
hiPSCs as no teratomas were observed in all of the tested animals (Fig. 5b,c). Also, the shape and histology of the 
testes were normal (Fig. 5d). In contrast, all animals transplanted with either Ctrl-miR switch sorted cells or with 
hiPS cells only developed enlarged teratoma formation. Further microscopic observation by Haematoxylin and 
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Eosin (H&E) staining showed these teratomas contained tissues reminiscent of the three main developmental 
lineages: ectoderm, mesoderm and endoderm (Fig. 5e).
Automated elimination of residual undifferentiated cells without cell sorting. A major advan-
tage of our strategy is that we can place any gene as the reporter on the miR-302a switch. Therefore, we hypoth-
esised that placing a simple puromycin selection circuit using puromycin-resistant mRNA (puroR) under the 
translational regulation of miR-302a switch would allow for automated elimination of residual hiPSCs without 
the need for cell sorting (Fig. 6a). We chose puromycin selection because of the ease of the design and puromycin 
is already used globally to form stable clones and has very little bystander effects on neighbouring cells. Firstly this 
design allows us to remove untransfected cells by adding puromycin. In cells that express active miR-302a, the 
miR-switch will repress the translation of the downstream puroR gene. Thus, upon supplementing the medium 
with puromycin, these cells will die. In contrast cells unresponsive to miR-302a switch will survive (Fig. 6a). 
Initially, we optimised the experimental conditions to assess toxicity of the puromycin. We found 2 μ g/ml 
was sufficient to give complete toxicity for both hiPSCs and differentiated mDA cells (Supplementary Fig. 5). 
Approximately 10 ng of puroR mRNA (in 96-well plate scale) was enough to restore cell viability under 2 μ g/mL 
puromycin. When regulating the puroR translation with miR-302a switch, we observed significant cell toxicity in 
hiPSCs but not in differentiated mDA neuronal cultures (Supplementary Fig. 5b).
Having succeeded in showing cell-specific toxicity with miR-302a-puroR switch in single culture, we then 
aimed to eliminate hiPSCs co-cultured with differentiated mDA cells. To eliminate the possibility that the cul-
turing condition itself could lead to the loss of hiPSCs irrespective of the puromycin selection, we co-cultured 
in hiPSC culture medium rather than mDA medium or a mixture of the two. To identify the original input cells 
more easily, we differentiated from a 201B7 line containing a single integrated EGFP gene driven by a constitu-
tive CAG promoter (201B7:EGFP) and stained with TRA-1–60 to identify hiPSCs (gating of populations shown 
in Supplementary Fig. 6). Compared to Ctrl-puroR switch-transfected co-cultures, 302a-puroR switch could 
Figure 3. Detection sensitivity for spiked hiPSC cells with miR-302a switch. (a) Representative dot plots of 
hmAG vs. tagBFP fluorescence for day 12 mDA cells spiked with 5%, 2.5%, 0.5%, 0.25% and 0.05% hiPS cells 
and transfected with 90 ng of miR-302a switch mRNA and 180 ng of tagBFP, and stained with anti-TRA-1-60 
antibody before flow cytometry (Supplementary Fig. 4). (b) The table summarises percentage of 302-pos, 302-
neg, TRA-1-60-pos, and TRA-1-60-neg cells for different hiPSC spike numbers (three independent experiments 
each).
www.nature.com/scientificreports/
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Figure 4. Sorting of partially differentiated mDA cells using the miR-302a switch. (a) Schematic of the 
experimental procedure. hiPSCs were partially differentiated through the mDA differentiation protocol for 4 
days and passaged to a new 6-well plate for reverse transfection of miR-302a switch and sorted into 302-pos and 
302-neg fractions for RT-qPCR analysis or recultured for later alkaline phosphatase staining. (b) Fold change 
in miR-302a-5p and 367-3p expression for the 302-neg fraction relative to the 302-pos fraction and normalized 
with RNU6B expression from snap-frozen cells sorted on day 5 (n = 3 for all groups). (c) Relative RT-qPCR 
gene expressions from 302-neg to 302-pos fractions and normalized by GADPH from snap-frozen cells sorted 
on day 5 (n = 3 for all groups). (d) Representative bright-field images of sorted cells recultured in hiPSC 
medium for a further 7 days and (below) the counted number of ALP-pos colonies. The TRA-1-60-pos and -neg 
fractions were sorted from non-transfected cells stained with an anti-TRA-1-60 antibody. Error bars represent 
the SEM of three independent experiments.
www.nature.com/scientificreports/
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efficiently eliminate TRA-1-60-pos cells to enrich EGFP-pos cells (201B7:EGFP-derived mDA cells), suggesting 
that it can remove undifferentiated cells without the requirement of sorting (Fig. 6b and Supplementary Fig. 6).
Figure 5. Transplantation of miR-302a switch-sorted cells. (a) Schematic of the experiment and 
representative dot plots of the sorted cells including gating. (b) Number of teratomas formed in mice 
transplanted with hiPSCs alone (positive control), mDA day 20 cells alone (negative control), Ctrl-miR switch-
sorted cells, and miR-302a switch-sorted cells (n = 4 for all groups). (c) Photos and macroscopic inspection of 
the testes taken from SCID mice transplanted with sorted or unsorted cells. (d) Representative H&E stained 
cryo-sections illustrate normal testes morphology of SCID mice transplanted with mDA D20 cells alone or 
spiked mDA D20 cells sorted with miR-302a switch. (e) Representative H&E stained cryo-sections showing the 
generation of all three germ layers within the biopsied teratomas.
www.nature.com/scientificreports/
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Discussion
To provide effective cell therapies that use iPSC technology, the transplanted cells must be devoid of residual 
undifferentiated and/or partially differentiated cells that will lead to teratoma formation or graft overgrowth 
respectively. Making use of miRNA switches, which can be used to identify live cells based on the cells’ unique 
miRNA activity signatures, we set out to develop a method that is highly specific and sensitive for eliminating 
out pluripotent cells and differentiation-retardant cells. To our knowledge, the miR-302a switch is the only meth-
odology that identifies, purifies, and/or eliminates target pluripotent stem cells based on intracellular signatures. 
The miR-302/367 cluster expression is necessary for maintaining the self-renewal of pluripotent cells and also an 
upstream regulator for many classical stem cell markers such as TRA-1-60, placental-like alkaline phosphatase 
and the intracellular transcription factors OCT3/4 and NANOG, which can only be measured in fixed or lysed 
cells25,26. Using this cluster, we engineered a very sensitive method that can track the dynamics of differentiating 
live cells. It is also noteworthy that our miR-302 switch system eliminates undesired cells based on positive selec-
tion of fluorescent-reporter mRNAs (i.e., we can isolate fluorescent-reporter-positive (miR302-negative) cells). 
Thus, we can easily exclude both untransfected cells and miR-302-positive/undifferentiated cells.
Previous studies have reported methods to detect and/or eliminate residual hPSCs from target cell popula-
tions, including antibody staining combined with FACS27,28, small molecule- or recombinant protein-mediated 
hPSC staining or killing29–34, and RT-qPCR analysis of the pluripotent intracellular marker LIN2835,36. However, it 
Figure 6. Automated purification of differentiated cells without cell sorting. (a) Schematic and time course 
of the puromycin-purification experiment. In the representative dot plot both untransfected (UT) and 302-pos 
populations can be removed by the addition of puromycin as they do not express the puroR gene. (b) LEFT Bar 
chart shows the total cell number from the entire cell suspension volume counted in P1/whole-cell- (white), 
7-ADD neg- (grey), EGFP pos- (green) and TRA-1-60 pos- (purple) gates after the stated treatments. UPPER 
RIGHT Representative histograms of EGFP fluorescence (7-ADD neg-gated cells) under conditions 2 μ g of 
puromycin with either 50 ng Ctrl-puroR switch (black shade) or 302a-puroR switch (green shade) (n = 3 for 
all groups). LOWER RIGHT Representative histograms of TRA-1-60 staining (7-ADD-neg gated cells) under 
conditions 2 μ g of puromycin with either Ctrl-puroR switch (black shade) or 302a-puroR switch (purple shade). 
Error bars represent the SEM of three independent experiments.
www.nature.com/scientificreports/
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is still difficult to detect undifferentiated cells (both hPSCs and partially differentiated cells) efficiently, selectively, 
and safely. For example, current issues surrounding the use of antibody staining, such as lot-to-lot variation37,38, 
non-specific binding38–40, and the retention of the antibodies on cell surface leading to localized immunogenicity41–43, 
further emphasises the need to develop alternative technologies. We believe our miR-switch method provides 
several advantages over the existing technologies as follows. (1) Using miR-puroR switch, we can avoid the neces-
sity for cell sorting, which can be time consuming and damaging to the cells (Fig. 6). Using additional syn-
thetic biology tools we may further tune our synthetic cell-killing circuit and more finely control the threshold 
between cell survival and cell death44. (2) Our miR-302a switch is highly sensitive and selective for the detection 
of hiPSCs and can be applied to any differentiation protocol because miR-302a activity can be used as a unique 
and robust hiPSC signature (ref. 45 and data in Fig. 1b and Supplementary Fig. 1a). In addition, we can uti-
lize multiple miRNA signatures by introducing multiple miRNA switches into the cells if needed12,13. (3) Our 
method has a high resolution for identifying cell sub-populations. Therefore the miR-302a switch may be used 
for both the detection of purely spiked hiPSCs27–33 and partially differentiated cells or cells that slowly differen-
tiate. Thus, our switch may be used to investigate the dynamics of differentiation and selection of optimal clones 
for directed-differentiation by monitoring miR-302a activity. For example, we consistently observed miR-302a 
switch-responsive cells up to day 9 of the mDA protocol despite being TRA-1-60 negative (Fig. 2d,e). We also 
observed that the 1231A3 hiPSC consistently gives higher mDA differentiation efficiency compared to 201B7 hiP-
SCs. If comparing miR-302a-responsive cells over time, the 1231A3 hiPSCs also differentiate quicker than 201B7 
hiPSCs. We believe removing residual miR-302a-responsive cells at earlier time points (e.g., day 5 in Fig. 2d) and 
re-culturing the negative fraction (miR-302a non-responsive cells) may lead to greater differentiation efficiencies. 
(4) Standard laboratory equipment and widely available kits are all that is required for our method. The amount of 
transfected RNA required is also minimal (500 ng of switch RNA/1 × 106 cells), therefore providing competitive 
cost effectiveness. We consistently observed transfection efficiencies of approximately 95% with multiple hiPSC 
lines and their derived cell types (Supplementary Table 3). Since antibody staining is not 100% efficient also, 
we believe our transfection efficiencies are an acceptable standard seeing that we can easily kill untransfected 
cells using puromycin selection. (5) Our miR switches should be safe to the cells because they are encoded on 
modRNA, which circumvents the issue of possible genomic integration seen with DNA encoded regulatory cir-
cuits44,46. Transfection of modRNA is a widely used method and several studies have shown it has very little if any 
toxicity on mammalian cells46. The transient expression of our miR switches also serves as an advantage, as we 
only need isolate the cells in a brief window of time. In fact, we previously have shown that miR switches do not 
significantly alter the steady-state expression of the target miRNA or expression of their target mRNA12.
The miRNA-302/367 cluster is so directly coupled with the stem-cell identity to the extent it can greatly 
increase reprogramming efficiency14,15,17,47,48, and so our miR-302a switch may also be used for purposes other 
than removing undifferentiated cells. Using an imaging cytometry approach13, we propose the possibility of iden-
tifying newly reprogrammed hiPSC cells from somatic cells in situ. Current methods require extensive train-
ing, as they require subjectively assessing the morphology of the cells/colonies by eye and then later confirming 
through replica plating and fixed-cell ALP staining21,49,50. Tracking the miR switch response of differentiated cells 
over time will also reveal information on the dynamics and assess different protocols for directed differentiation. 
Finally, our technology may provide greater insights into miRNA activity and pluripotency (e.g., the primed and 
naïve states of cells)51–55. So far, microarray and RNA-seq technologies have revealed miRNA expression differ-
ences between primed and naïve states of pluripotency in both mouse and humans, in particular members of the 
miR-302 and miR-371 (miR-290 in mouse) clusters54,56,57. However it is important to verify whether the expres-
sion differences translate to true activity differences, which we can do using our miR switch technology. A recent 
report has found approximately 60% of a cell’s detectable miRNAs have no or relatively weak activity58. Thus, our 
miR switch can be used as a basic research tool to investigate the dynamics of differentiation and reprograming of 
live cells using intracellular information.
Methods
Cell culture and reagents. Human iPSC lines (201B7, 1231A3, and 1383D7) were a kind gift from 
Dr. Masato Nakagawa & the CiRA FiT facility (Kyoto University). Normal human dermal fibroblast cells (NHDF; 
CC-2511) were purchased from Lonza (USA), and HeLa CCL-2 cells were obtained from the ATTC depository. 
StemFit AK03 medium was purchased from Ajinomoto Pharmaceuticals (Japan). Hank’s balanced salt solution 
(HBSS), Glasgow’s modified essential medium (GMEM), KnockOut serum replacement (KSR), Neurobasal A 
medium, and NB27 neural supplement were purchased from Life Technologies (USA). 100 sodium pyruvate 
solution, 1000×β -mercaptoethanol solution, and 100X β -glutamine solution were purchased from Sigma Aldrich 
(USA). iMatrix-511-E8 fragment was purchased from Nippi (Japan). Other tissue culture reagents were purchased 
from Life Technologies unless stated otherwise. Recombinant human FGF8 (Cat#063-04371), Purmorphamine 
(Cat#166-23991), and Y-27632 (Cat#08945-84) were purchased from Wako Pharmaceuticals (Japan). Dibutyl-
cyclicAMP (Cat#D0627-250MG) and ascorbic acid salt (Cat#A4034-100G) were purchased from Sigma. 
LDN193189 (Cat#04-0074), A83-01 (Cat#04-0014), and CHIR99021 (Cat#04-0004-10) were purchased from 
Stemgent. Recombinant human BDNF (Cat#248-BD-025) and recombinant human GDNF (Cat#212-GD) were 
purchased from R&D (USA). mirVana miRNA Mimic, Negative Control #1, mirVana miRNA Inhibitor Negative 
Control, hsa-miR-302-5p mimic (Pre-miR/Anit-miR ID:MC12557), and 302a-5p inhibitor (Pre-miR/Anti-miR 
ID:MH12557) were purchased from Applied Biosystems and used at the stated picomole amount.
hiPSC maintenance and differentiation. Feeder-free (Ff) hiPSC lines were grown attached to plates 
coated with laminin-511-E8 fragment (iMatrix, Nippi) in xeno-free defined StemFit medium AK03 medium 
(Ajinomoto). These methods are designed to obtain clinical-grade hiPSC with standard operating protocols59. 
hiPSCs were passaged once every 8 days. 6-well plates were coated at 37 °C for at least 1 hr before passage with 
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iMatrix-511(E8) at a density of 0.5 μ g/cm2 diluted in sterile PBS. The cells were passaged as previously pub-
lished59. For mDA differentiation, 6-well plates were coated the same as above with iMatrix-511-E8 and hiPSCs 
seeded at density of 5 × 106 cells/well. The cells over 12 days were induced to dopaminergic neurons in xeno-free 
conditions59. After 12 days, the cells were passaged and maintained in Neurobasal medium supplemented B27, 
GDNF, BDNF, ascorbic acid and dibutyl-cyclicAMP. Transfection of these mDA cells was either carried out in the 
same medium or the stated medium otherwise.
For spontaneous differentiation, Ff-hiPSC cells were plated onto 6-well coated plates at a density of 8 × 104 
cells/well and maintained in StemFit AK03 medium without the addition of bFGF for 14 days. After 7 days, cells 
were passaged using Accumuax to a new 6-well coated plate at density of 2.5 × 105 cells/well.
The 201B7-DD″ line was classified as differentiation-defective because this line consistently contains ~10% 
TRA-1-60-pos cells after differentiation. In contrast its parental line, 201B7, has less than 1% TRA-1-60-pos cells 
after differentiation. The 201B7-DD″ line was established by FACS-sorting for TRA-1-60-pos cells after each 
round of spontaneous differentiation (Supplementary Fig. 2). After the first round of differentiation, TRA-1-
60-pos cells (approximately 8%) were seeded and grown under normal hiPSC culture conditions and passaged 
once. The passage two cells were taken through a second round of differentiation. TRA-1-60-pos cells (approx-
imately 14%) were seeded and grown under normal hiPSC culture conditions and passaged once to establish 
201B7-DD″ before differentiating again for miR switch experiments.
Assessing differentiation efficiency. During each passage at D12 and D20, the efficiency of differentia-
tion was assessed by staining the bulk cells with a CORIN antibody from R&D Systems (MAB2209), a floor-plate 
marker and a PSA-NCAM antibody, which marks the neural lineage. Approximately 5 × 105 cells in 200 μ L of 
stain buffer (with ROCK inhibitor) in parallel were stained with either 1/200 of mouse anti-human CORIN anti-
body (R&D Systems) or 1/100 of mouse monoclonal anti-human PSA-NCAM (MAB5324, Millipore). Alexa 
488-conjugated anti-rat IgG or anti-mouse IgM antibodies were used at 1/400 for CORIN and PSA-NCAM, 
respectively. Cells were stained for 30 min at 4 °C. Cells were washed twice in HBSS medium. Dead cells were 
stained with 7-AAD for 10 min prior to FACS analysis.
Cells were analysed on either a BD FACS aria-II or BD Accuri with standard filters for FITC and 7-AAD sig-
nals. Gates were set up to eliminate dead cells based on SSC-A intensity (P1) and to remove doublets from FSC-W 
vs FSC-H (P2) and SSC-W vs SSC-H (P3). Finally 7-AAD high cells were excluded leaving the ‘LIVE’-cell gate 
(P4/LIVE). 20,000 P4-gated cells were analysed.
Template generation and in vitro transcription (IVT). In this study we in vitro transcribed 
modRNA and then transfected to the cells. The general method for the generation of the modRNA was detailed 
previously12,13. Three separate PCR reactions were carried out to produce a designed 5′ -untranslated region, ORF 
and a designed 3′ -UTR PCR products (Supplementary Table 1). The 5′ -UTR products were amplified from the 
oligos listed using either TAP_T73GC (Ctrl-miR switch) or GCT7pro_5UTR2 (302/367-miR switch) forward 
primer and Rev5UTR reverse primer. Similarly, the 3′ -UTR products were amplified from the oligos listed using 
the Fwd3UTR forward primer and 3′ UTR_2T20Trev reverse primer. The ORF products were amplified using the 
forward and primers listed. The following products were then combined into one full-length PCR product using 
fusion PCR with an additional 120 nt polyA sequence, which extends the stability of the transcribed mRNA. The 
5′ end contains a T7 promoter, which can bind to the T7 RNA polymerase used in commercial IVT kits. For the 
miR-responsive switch, anti-sense sequence for the target miRNA was inserted into an optimised position in the 
5-UTR to allow for translational repression of the downstream reporter if bound to this miRNA. The target sites 
for hsa-miR-302a-5p and 367-3p are underlined and in bold in the primer list (Supplementary Table 1).
RT-qPCR. Relative miRNA expression was carried out using TaqMan small RNA assays for hsa-miR-302a-5p 
(Assay ID: 002381), 367-3p (Assay ID: 000555), and RNU6B (Assay ID: 001093). Cells for RNA analysis were first 
pelleted, medium aspirated, and then snap frozen in liquid nitrogen and stored at − 80 °C. Pellets were thawed 
on ice and then rapidly resuspended in Trizol for RNA extraction following the manufacturer’s protocol. Pelleted 
RNA was resuspended in RNAse-free water treated with TURBO DNase inactivation kit following the manufac-
turer’s protocol. Total RNA was assessed by Agilent Bioanalyzer with RIN > 8 for all samples tested. First strand 
synthesis was carried out using 10 ng of RNA, the miRNA-specific TaqMan RT primer and the MultiScribe RTase 
kit. PCR amplification was done by miRNA-specific TaqMan fluorescent probes and TaqMan Fast Universal PCR 
Master Mix (2X), no AmpErase UNG on Applied Biosystems StepOne in realtime. miRNA was normalized to the 
small RNA, RNU6B.
For messenger RNA analysis, reverse transcription was carried out using 1 μ g of RNA, random hexamer prim-
ers and the TOYOBO ReverTra Ace-α kit following the manufacturer’s instructions. Primers for real-time ampli-
fication are listed in Supplementary Table 2 and were found to give efficiencies close to 2 from initial optimisation. 
10 ng of cDNA input was amplified with Power SYBR Green PCR Master Mix for 40 cycles followed by melt-curve 
analysis. Target mRNA was normalized to GADPH. Raw Ct values were analysed and presented using the Pfaffle 
Δ Δ Ct method60.
RNA Transfection. A day before transfection, cells were passaged as detailed above and seeded onto 
iMatrix-511 (E8) coated 24-well plates at density from 1–2 × 105 cells/well in differentiation medium (with 
ROCK inhibitor). The following day, without changing the medium, modRNA was transfected to the cells using 
StemFect reagent (Stemgent) following the online protocol. Briefly for each transfection, in one tube (tube A), 
1 μ L of reagent was mixed with 12.5 μ L of StemFect buffer and incubated for 5 min at room temperature (RT). In 
another tube (tube B), up to 400 ng of modRNA was mixed with 12.5 μ L of StemFect buffer. Tube B was added 
to tube A in a drop-wise manner, and the mixture was briefly flick-mixed and incubated for 10 min at RT. The 
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transfection complex was added to the cells in a drop-wise manner and the plate was agitated before being placed 
into the incubator. Four hours later, the old medium containing the complex was aspirated and fresh differenti-
ation medium (without ROCK inhibitor) was added. For the experiments in Fig. 4, transfection complexes were 
formed as above but were added to the cell suspensions during seeding of the cells to culture plates on the same 
day of passaging.
Cells were analysed the following day by FACS analysis on either a BD FACS Aria-II or BD Accuri using 
standard filter sets and similar gating for antibody staining. The transfection efficiency was judged against 
mock-transfected cells. In the case of reverse transfection, the complex was mixed with the cell suspension on the 
day of passage when seeded to new plates.
To control for variation in the transfection efficiency between cells, signals from the switch were normalized 
to that of an internal control. For the tagBFP-pos population (usually > 90% of live-cells), the geometric mean 
of the fluorescence intensity (arbitrary units) for hmAG was divided by that of tagBFP to give the normalized 
translation efficiency. The normalized translation efficiency was then expressed as percentage of Ctrl-miR switch 
transfected cells in the bar charts.
In vivo tumorigenicity assay. Purified or non-purified cells were injected into the testes of SCID mice. 
Cells were checked for mycoplasma presence before transplanting in order to prevent infection. 201B7 hiPSCs 
were differentiated to mDA for 20 days. The differentiated cells were passaged and seeded into 12-well plates, 
some of which were spiked with 201B7 hiPSCs, at a final density of 0.75 × 105 cells/cm2. The following day, wells 
spiked with hiPSC were transfected with either 180 ng of Ctrl-hmAG1 or 302a-5p-hmAG1 and 400 ng of tagBFP. 
After 24 hr, cells were sorted using FACS Aria-IIu and collected into StemFit AK03 medium containing ROCKi. 
2 × 104 201B7 hiPSCs were injected into both testes of 3 animals. 2 × 105 of non-sorted mDA D20 cells, Ctrl-miR 
switch-sorted hiPSC-spiked mDA culture, and miR-302a switch-sorted hiPSC-spiked mDA culture were injected 
into both testes of 4 animals for each group. After 3 months, animals were sacrificed, and the testes dissected out 
from the body. Images were taken to record macroscopic appearance and then the tissue was fixed in saline solu-
tion, sectioned and H&E stained to observe microscopic tissue morphology.
The animal experiments were performed in accordance with the guidelines and regulations for Animal 
Experiments of Kyoto University and approved by the same institution.
Puromycin purification. Single and co-cultures cells were treated as shown in Fig. 6a and Supplementary 
Fig. 5a. One day before transfection, cells were passaged and seeded into 24-well plates. Even though we found 
the action of puromycin to override the anti-apoptotic effect of the ROCK inhibitor used for hiPSC passaging, we 
decided to change the medium 2 hr before transfection to remove the inhibitor. Four hours after transfection, the 
medium was changed again and included puromycin at 2 μ g/mL. For the WST-1 cell viability assay (Roche), fresh 
medium containing WST-1 substrate was added 2 days after transfection and incubated for 4 hr before reading 
absorbance at the recommended wavelength on TECAN microplate reader (Infinite M1000).
For the experiments in Fig. 6, cells were washed twice with 1xPBS one day after transfection to remove dead 
and dying cells. Cells were harvested with trypsin, pelleted and re-suspended in stain buffer (HBSS and 2% knock-
out serum). Cells were then stained with an Alexa 647-conjugated anti-TRA-1-60 antibody (BD Laboratories) 
for 20 min at 4 °C, washed twice with stain buffer and finally stained with the 7-AAD dye in 150 μ l stain buffer. 
The entire cell suspension volume of harvested cells was analysed on a BD Accuri cell cytometer. Representative 
dot plots and corresponding gating can be seen in Supplementary Fig. 6 for the following parameters: SSC-A vs. 
7-ADD, and TRA-1-60 vs. EGFP. The live cell gate, P1-gate, was established on FSC vs. SSC signal to eliminate 
cell debris and most of the dead cells and on the SSC vs. 7-AAD signal to remove any remaining dead intact cells.
Statistical analysis. FACS dot plots and histograms were produced in FlowJo software for Mac. Significant 
differences between means were statistically tested to the 5% confidence level using either non-parametric t-test 
when referring only to the control or one-way ANOVA followed by post-hoc test when comparing all groups. The 
levels of significance are denoted as; *P < 0.05, **P < 0.01, and ***P < 0.001. The statistical analysis is based on the 
means generated from at least three independent experiments performed on separate days.
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